• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcoHomeThis ArticleSearchSubmitASCO JCO Homepage
J Clin Oncol. May 10, 2010; 28(14): 2467–2474.
Published online Apr 5, 2010. doi:  10.1200/JCO.2009.26.6213
PMCID: PMC2881725

Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 Genes Involved in the Double-Strand Break Repair Pathway Predict Glioblastoma Survival

Abstract

Purpose

Glioblastoma (GBM) is the most common and aggressive type of glioma and has the poorest survival. However, a small percentage of patients with GBM survive well beyond the established median. Therefore, identifying the genetic variants that influence this small number of unusually long-term survivors may provide important insight into tumor biology and treatment.

Patients and Methods

Among 590 patients with primary GBM, we evaluated associations of survival with the 100 top-ranking glioma susceptibility single nucleotide polymorphisms from our previous genome-wide association study using Cox regression models. We also compared differences in genetic variation between short-term survivors (STS; ≤ 12 months) and long-term survivors (LTS; ≥ 36 months), and explored classification and regression tree analysis for survival data. We tested results using two independent series totaling 543 GBMs.

Results

We identified LIG4 rs7325927 and BTBD2 rs11670188 as predictors of STS in GBM and CCDC26 rs10464870 and rs891835, HMGA2 rs1563834, and RTEL1 rs2297440 as predictors of LTS. Further survival tree analysis revealed that patients ≥ 50 years old with LIG4 rs7325927 (V) had the worst survival (median survival time, 1.2 years) and exhibited the highest risk of death (hazard ratio, 17.53; 95% CI, 4.27 to 71.97) compared with younger patients with combined RTEL1 rs2297440 (V) and HMGA2 rs1563834 (V) genotypes (median survival time, 7.8 years).

Conclusion

Polymorphisms in the LIG4, BTBD2, HMGA2, and RTEL1 genes, which are involved in the double-strand break repair pathway, are associated with GBM survival.

INTRODUCTION

Glioblastoma (GBM) is the most common and most malignant primary brain tumor in US and European countries, with an annual incidence of approximately three in 100,000 people newly diagnosed each year.1 Despite recent advances in treatment including surgical resection followed by concurrent chemotherapy with radiation, the median survival remains approximately 9 to 15 months.2 Nevertheless, a subset of patients survived for longer than 3 years. Although certain clinical features, such as younger age, good Karnofsky performance status at the time of diagnosis, and extent of resection, are well-known prognostic parameters.35 However, it is likely that other, as-yet-unknown genetic factors may help predict which patients are more likely to have this prolonged survival. Therefore, it is important to determine the genetic factors that influence survival for this rapidly fatal disease and, by doing so, perhaps uncover the molecular signatures of long-term survivorship.

Subtypes of GBM exist, despite indistinguishable features by pathologic evaluation with differing survival durations and responses to treatment.6 Some genetic aberrations in GBM have been known for years, such as MGMT, ERBB2, EGFR, TP53, and PTEN.79 Recent studies demonstrated that mutations in IDH110 and alterations in multiple networking genes (POLD2, CYCS, MYC, AKR1C3, YME1L1, ANXA7, and PDCD4)11 were associated with GBM survival. Polymorphisms in TERT,12 IL4R,13 EGF,14,15 and CX3CR116 genes and GBM survival have also been described. However, to date, no prognostic biomarkers have been found to be sufficiently reliable or useful for clinical practice.

Recently, our group17 and others18 found, using GWAS (genome-wide association study) methods, several single nucleotide polymorphisms (SNPs) that were strongly associated with glioma susceptibility. However, both of those studies focused on cancer susceptibility rather than outcomes. For this study, we applied a survival analysis to the 100 top-ranking glioma susceptibility SNPs from the GWAS to determine whether they were also associated with GBM survival. We used two analytic strategies to fulfill this goal. First, we examined overall survival in 590 patients with GBM. Second, to determine whether there are specific genetic variations that distinguish long-term survivors (LTS; survival ≥ 36 months) from short-term survivors (STS; survival ≤ 12 months), we further compared the differences in gene variations in 97 LTS and 202 STS. We then tested our findings in two additional independent data series.

PATIENTS AND METHODS

Study Population

The population for this study was a subset of GBMs from a prospective study of patients with malignant glioma (N = 1,304) consecutively diagnosed and treated at The University of Texas M. D. Anderson Cancer Center (MDACC), Houston, TX.17,19 The patients were participants in an ongoing glioma epidemiology study from 1992 to 2008, with follow-up until May 2009. We selected primary patients with GBM (International Classification of Diseases code 94403) who were ≥ 18 years old at the time of diagnosis. We only included white patients because there are very few non-white patients—11 Hispanic, 12 African American, and three Asian for any meaningful analyses.

Treatment and survival data (dates of death or last contact) were collected retrospectively from medical record review for all patients. Dates of death were confirmed by querying the Social Security Death Index. From the obtained data, we observed patients from the earliest date of registration at MDACC in May 1992 to the date of last contact or death through May 2009. The follow-up periods ranged from 1 month to 17 years (ie, 204 months). The study was approved by M. D. Anderson institutional review board, and written informed consent was obtained from each participant.

Subjects for the Replication Phase

As a validation group, we obtained data for patients from two other institutions (Appendix A1, online only). The first group included 352 newly diagnosed patients with GBM who were seen at the University of California, San Francisco (UCSF) between 2001 and 2006.18 The second group included 191 patients with GBM ascertained in an outcome study at Umeå University Hospital accrued 2002 to 2007.

Selection of the SNPs and Genotyping Assays

The top-ranking 100 glioma susceptibility SNPs with the smallest P values in our GWAS were selected and examined in this study (Appendix Table A2, online only). We contracted with Illumina to conduct the genotyping using the Human 610-Quad Bead Chips (Illumina, San Diego, CA). Subsequent genotyping of SNPs was conducted using either the Illumina 317k chip by decode Genetics (UCSF samples) or single-base primer extension chemistry matrix assisted laser desorption and ionization time of flight mass spectrometry detection by Sequenom (Swedish samples).

Statistical Methods

Survival time was defined as the time between the date of diagnosis and date of death for deceased patients or the last contact date for living patients. The overall survival time was estimated using Kaplan-Meier methods, and log-rank analysis was performed to compare survival curves between groups. Hazard ratios (HRs) and their corresponding 95% CIs were estimated using Cox regression, with adjustment for age, sex, and extent of resection. Genotype frequencies of the LTS and the STS were compared using χ2 tests. We calculated the odds ratios (ORs) and 95% CIs by unconditional logistic regression analysis with adjustment for diagnosis age, sex, and extent of resection.

To evaluate the chance of obtaining a false-positive association in our data set, we used the false-positive report probability (FPRP) test20 and the Bayesian false-discovery probability (BFDP) test.21 For our analyses, we used the moderate range of prior probabilities .08 and .05; the FPRP and BFDP cutoff value of .2 and .8, respectively, as suggested by the authors for summary analyses.20,21

Finally, we produced a classification and regression tree (CART) for survival data to identify higher-order interactions between clinical factors and genetic variants using the RPART package22 in S-PLUS Version 8.0.4 (TIBCO, Palo Alto, CA). CART is a prognostic system with a hierarchical structure, based on recursive portioning that build a decision tree to identify subgroups at higher risk of death. Specifically, the recursive procedure starts at the root node and uses a log-rank statistic to determine the first optimal split and each subsequent split of the data set. This process continues until the terminal nodes have no subsequent statistically significant splits or the terminal nodes reach a prespecified minimum size (n > 10). Each end node contains the numbers of total and censored observations falling into the current category, as well as a HR and 95% CI adjusted by age, sex, and extent of resection. The reference group is the one with the smallest percentage of censored observations. Kaplan-Meier estimation of the cumulative survival for each subgroup was also performed; log-rank P value was set to indicate significance.

RESULTS

Patient Characteristics

The final population of the MDACC study consisted of 590 patients with primary GBM (Table 1). At the end of our study (May 2009), 544 (92.2%) of 590 patients with GBM had died. The median survival time (MST) was 22.63 months. Among these 590 patients with GBM, 202 were STS, and 97 were LTS (52 survived ≥ 5 years). The MST was 7.8 and 76.1 months in the STS and LTS, respectively. No patients survived in the STS, whereas 48 (49.5%) were still alive in the LTS.

Table 1.
Demographics and Treatment Information for the Study Population

Examinations of the demographic data for the LTS and STS shows that patients in the LTS (mean age, 48.1 years) were significantly younger than patients in the STS (mean age, 55.9 years; P < .001). Also, patients in the LTS were much more likely to have undergone a gross total resection than were patients in the STS (57.6% v 21.6%; P < .001).

Association Between SNPs and Overall Survival

Of the 100 SNPs evaluated, six showed a statistically significantly correlation with overall survival according to the log-rank test and Cox regression analysis (Table 2). LIG4 rs7325927, BTBD2 rs11670188, RGS22 rs4734443, and chromosome 3 rs13099725 were associated with STS, whereas RTEL1 rs2297440 and rs6010620 were associated with LTS. A strong gene-dosage effect on survival was observed when the six SNPs were analyzed in combination (Table 2), with highly significant differences for overall survival (log-rank P < .001). The MST decreased progressively as the number of at-risk SNPs increased.

Table 2.
Association Between Genotype and Overall Survival (N = 590)

Association of SNPs With Long-Term Survival Between LTS and STS

Eight SNPs were statistically different between LTS and STS. As presented in Table 3, LIG4 rs7325927 and BTBD2 rs11670188 were associated with STS, whereas CCDC26 rs10464870 and rs891835 (in strong linkage disequilibrium [LD]), VPS8 rs6765837, RTEL1 rs2297440, and rs6010620 (in strong LD), HMGA2 rs1563834 were associated with LTS. The joint effect of these combined eight SNPs showed that the risk of early death increased progressively as the number of at-risk SNPs increased (P trend < .001).

Table 3.
Association Between the STS and LTS

To evaluate the robustness of these findings, we calculated FPRP and BFDP values at two levels of prior probabilities (.08 and .05) for the eight SNPs (Table 4). At a prior probability level of .08, six of these eight SNPs (LIG4 rs7325927, BTBD2 rs11670188, CCDC26 rs10464870 and rs891835, VPS8 rs6765837, and RTEL1 rs2297440) remained noteworthy (FPRP ≤ 0.2, or BFDP ≤ 0.8). At a very low prior probability of .05, only LIG4 rs7325927 remained noteworthy.

Table 4.
FPRP and BFDP Values for the Significant SNPs on Associations of Between the STS and LTS

Survival Tree Analysis

We built a survival tree using the clinical variables (age and sex) and the six SNPs that were found to be noteworthy at prior probability of 0.08. Figure 1A depicts the survival tree structure generated by CART analysis. The first split on the decision tree was age, confirming that age was the most important risk factor among those considered. Further inspection of the tree structure suggested distinct patterns of survival, resulting seven terminal nodes belonging to two sides of the tree. In particular, young patients (≤ 50 years) with combined variant type (V) of RTEL1 rs2297440 and HMGA2 rs1563834 had the best prognosis, MST 93.9 months (7.8 years; node 1). This subgroup has 10 patients, all were LTS, and eight of them were still alive. Using node 1 as reference group, the young individuals with wild type (W) of RTEL1 rs2297440, BTBD2 rs11670188 (V), and CCDC26 rs10464870 (W) exhibited worse survival (MST, 13.8 months; node 5) and a 16-fold risk of death (HR, 16.84; 95% CI, 3.88 to 73.04). Node 5 has 19 patients, all of them were deceased. Likewise, the older patients (> 50 years) with LIG4 rs7325927 (V) also showed a very short survival time (MST, 14.8 months; node 7) and exhibited the highest risk of death (HR, 17.53, 95% CI, 4.27 to 71.97), supporting the protective effect of RTEL1, HMGA2, and CCDC26, and risk effect of old age, BTBD2 and LIG4 found in the main effect analysis. Figure 1B shows the Kaplan-Meier estimates of cumulative survival for each end node.

Fig 1.
Survival tree analysis. (A) Survival tree. The number of patients and events/deceased are indicated in the nodes. (B) Kaplan-Meier curves of survival times in patients for seven nodes. Node1 had a significantly improved prognosis, with a median survival ...

Replication Results

We further looked at the six noteworthy SNPs (LIG4 rs7325927, BTBD2 rs11670188, CCDC26 rs10464870 and rs891835, VPS8 rs6765837, and RTEL1 rs2297440) using two independent series. In the UCSF study, except for VPS8 rs6765837, all of other five SNPs were available for confirmation. In the Swedish study, VPS8 rs6765837 and BTBD2 rs11670188 were unavailable for analysis. The confirmation analysis was adjusted for age and sex. Only the heterozygote of BTBD2 rs11670188 in UCSF group showed significant association with overall survival (HR, 1.31; 95% CI, 1.03 to 1.68; Appendix Table A3, online only). None of the SNPs were significantly different between STS and LTS in both replication data sets (data not shown).

DISCUSSION

In this study, we identified LIG4 rs7325927 and BTBD2 rs11670188 as predictors of STS in GBM and CCDC26 rs10464870 and rs891835, HMGA2 rs1563834, and RTEL1 rs2297440 as predictors of LTS. Consistent with most other studies,23 we found age at diagnosis to be a very important predictive factor in GBM survival. In the Surveillance, Epidemiology and End Results data, 5-year survival rates are approximately 13% for 15 to 45 year olds and only 1% for those ≥ 75 years old.24 Our LTS (mean age, 48.1 years) was significantly younger than the STS (mean age, 55.9 years). Moreover, age is the initial split on the survival tree, confirming that age is the most important risk factor. Further, different genes play roles in different age group. The older patients (> 50 years) with variant type of LIG4 rs7325927 showed the worst prognosis; whereas young patients (≤ 50 years) with combined variant type of RTEL1 rs2297440 and HMGA2 rs1563834 had the best prognosis.

A major finding in this study was the consistent association of LIG4 rs7325927 with STS. LIG4 rs7325927 was the only noteworthy SNP at the FPRP low prior probability of .05. Survival tree analysis showed that older patients with LIG4 rs7325927 (V) exhibited the highest risk of death, which strongly suggests that LIG4 rs7325927 or a genetic variant in LD with this SNP is associated with STS. LIG4 (DNA ligase IV; OMIM 601837) is essential for V(D)J recombination and DNA double-strand break repair (DSBR) through nonhomologous end joining (NHEJ). As a critical protein involved in NHEJ, LIG4 forms a heterodimer with XRCC4 to execute the final rejoining step of NHEJ. Polymorphisms of this gene have been related to risk of glioma25 and multiple myeloma,26 as well as to the survival of breast cancer.27

Another promising finding is the association of BTBD2 rs11670188 with STS. Coincidentally, BTBD2 (blood-tumor barrier modification; OMIM 608531) has also been implicated in DSBR pathway because of its tight interaction with Top1. Top1 can cause double-stranded breaks28 and plays a central role in regulating cell survival.29,30 Bredel et al31 have shown that high expression of DNA Top II alpha is associated with prolonged survival in patients with GBM. The CCDC26, HMGA2, and RTEL1 genes are also of interest. CCDC26 modulates retinoic acid, which in turn increases programmed cell death in GBM cells and reduces telomerase activity3234; whereas both HMGA2 (high-mobility group protein family, member 2; OMIM 600698)35,36 and RTEL1 (regulator of telomere elongation helicase 1; OMIM 608833)37 were recently proved to be directly involved in DSBR pathway.

It is interesting to note that of the five important genes noted in this study, four (LIG4, BTBD2, HMGA2, and RTEL1) are directly or indirectly involved in the DSBR pathway, suggesting a very strong genetic interaction network. This is particularly intriguing because DSBR plays a prominent role in cell survival, maintenance of genomic integrity, and prevention of tumorigenesis. DSBs can be generated by endogenous reactive oxygen species or destabilization of stalled replication forks as well as by exposure to a variety of exogenous agents, including ionizing radiation (IR) and chemotherapeutic agents. Furthermore, IR is the only established risk factor for glioma,3840 and IR is also used in cancer radiation therapy. Germline variation in DSBR capabilities may affect survival because of altered response to radiation or chemotherapy. Therefore, understanding how these DSBR genes and SNPs function epistatically in the same biologic pathway that influences survival of patients with GBM, whether as enhancers or inhibitors of response to radiation or chemotherapy would be very interesting in future studies.

Although our study demonstrates a strong association of certain SNPs with outcome, and there is biologic plausibility for the associations observed in our study. However, there are limitations of our study. The main one is that most of our findings did not reach statistically significant level in the replication series. However, replication failure should not be surprising or be interpreted as necessarily refuting the initial findings because of the potential problems such as population stratification. Our study and the UCSF study are clinic based while the Swedish study was mainly population based. When comparing the characteristics of the three groups, we observed large discrepancies in age at diagnosis (median 52 years in ours v 56 in Swedish and UCSF cases), and survival time (MST 22.6 months in our data set v 16.3 in the UCSF, 13.9 months in Swedish set).

Genetic heterogeneity—this heterogeneity may exist even in populations of the same ethnic group such as whites with European ancestry.41,42 We compared the distribution of four SNPs in the three groups, and found one (LIG4 rs7325927) was significant in our data set versus Swedish and UCSF, one (RTEL1 rs2297440) was marginal significant in ours and Swedish versus UCSF (Appendix Table A4, online only), indicating differences in the case populations. Different environmental exposures and different patterns of care would also lead to greater difficulties in replication. As raised by Morgan et al,43 replication studies face the risk of nonvalidation because of the lack of generalizability, especially in a heterogeneous treatment population for a pathologically and clinically heterogeneous tumor such as GBMs (GBM, the glioblastoma “multiforme,” the latter term now taken away, was a very useful reminder of this fact). Gorroochurn et al44 point out, “even if these problems were to be remedied, trying to replicate many initial findings, even if they are quite significant, maybe be predisposed to failure and should not be interpret as necessarily contradiction the initial association.” The same feeling has been echoed elsewhere,45 and Liu et al46 have provided a theoretical justification. Thus, on a second look, replication, while important and valuable, is difficult to achieve and may not be sufficient or necessary. Additional information from other lines of evidence, such as detailed molecular mechanistic studies, may be useful for validating and illuminating the functional relevance of genes identified in our study.

Another limitation is the possibility of effect change in treatment on survival because first-line GBM treatment has been changed from involved-field cranial irradiation to chemoirradiation with daily temozolomide in 2005. However, among 590 patients with GBM, 93.6% (552) were diagnosed before 2005; only 6.4%38 were diagnosed after 2005, and none of them were LTS. Therefore, we do not think that there will be any bias toward genes that are important for DNA repairs. The third limitation is the potential limited applicability of the findings to other ethnic groups, such as African Americans, Asians, and Hispanics.

In conclusion, we have provided evidence to implicate that LIG4 rs7325927 and BTBD2 rs11670188 are predictors of GBM STS and that CCDC26 rs10464870 and rs891835, RTEL1 rs2297440 and rs6010620, and HMGA2 rs1563834 are predictors of LTS. It is highly likely that the polymorphisms of these genes, which are directly or indirectly involved in the DSBR pathway, will be novel and potentially prognostic biomarkers for GBM survival, and this could be the beginning of a risk assessment model that could predict which patients would be LTS or STS.

Acknowledgment

We thank P. Adatto, F. Morice, H. Zhang, V. Levin, A. Yung, Sawaya, V. Puduvalli, C. Conrad and J. Weinberg from the Brain and Spine Center; V. Mohlere for scientific editing; and the study subjects for their participation.

Appendix

Table A1.

Frequency Distribution of Selected Characteristics of Study Subjects in UCSF and Sweden Replication Groups

VariableUCSF (N = 352)
Sweden (N = 191)
No. of PatientsNo. of DeathsMST (months)No. of PatientsNo. of DeathsMST (months)
All35230016.319116513.9
Age
    ≤ 501209220.4504015.6
    > 5023220814.414112513.2
Sex
    Male22919416.211710412.7
    Female12310618.2746121.8
Radiation therapy
    No886.7NA
    Yes34429217.1
Chemotherapy
    No chemotherapy24229.8NA
    Temodar given29124517.8
    Other chemotherapy363215.9
Extent of surgical resection
    Biopsy only292611.6NA
    Resection32327417.1

Abbreviations: UCSF, University of California San Francisco; MST, median survival time; NA, not available.

Table A2.

Information About 100 Top Ranking Glioma Susceptibility SNPs From Our Previous Glioma GWAS

SNPChrGeneBase ChangeMAF
Log-Rank Pχ2 Test P
NCBIMDACC CasesCodominantDominantRecessive
rs130997253C3orf56A/G0.150.15.002.043.35.032
rs47344438RGS22C/T0.4580.38.003.067.87.033
rs732592713LIG4C/T0.2250.29.008.027.004.052
rs1167018819BTBD2A/G0.2170.23.009.036.02.25
rs229744020RTEL1C/T0.2580.18.02.038.024.083
rs601062020RTEL1A/G0.2580.19.021.051.041.17
rs13809948RGS22A/G0.4670.39.038.0771.033
rs96569798CCDC26C/T0.4070.45.0381.05.23.12
rs1013103214AKAP6A/G0.1080.08.0435.13.14.079
rs27813211DAB1A/G0.4580.47.0632.57.31.91
rs109245591SMYD3A/G0.0440.16.0671.64.56.53
rs209435413LOC644623A/G0.1250.07.069.41.8.21
rs150993710CTNNA3A/G0.3830.36.1006.073.49.065
rs21109222SLC8A1G/T0.3920.39.1028.09.091.03
rs951404413C13orf39C/T0.1750.27.113.27.16.24
rs104648708CCDC26C/T0.1750.23.1137.018.011.017
rs67658373VPS8C/T0.4670.46.121.046.025.79
rs177454842DNMT3AC/T0.3250.36.1422.12.076.61
rs156383412HMGA2A/G0.1020.14.1462.056.045.027
rs37708762CRIM1A/C0.3530.45.1662.045.041.054
rs20088820PTPNS1G/T0.4170.41.1785.4.22.36
rs132683648PEBP4C/T0.2670.28.1876.019.13.052
rs16816553TBL1XR1C/T0.1330.09.1922.015.22.31
rs17112516TP53TG3A/G0.1470.11.2603.26.24.21
rs75135531PPT1G/T0.1860.21.2626.2.075.49
rs728222721C21orf37C/T0.0750.07.2658.19.14.38
rs78497959C9orf123G/T0.2590.2.3161.17.56.06
rs134094910LOC220929C/T0.4750.42.3192.28.54.24
rs992294316SLC38A8C/T0.150.2.3271.5.62.24
rs8918358CCDC26G/T0.1750.24.3308.011.024.013
rs102296927CNTNAP2A/G0.0590.09.3327.46.62.22
rs1014920814LOC729646A/G0.4350.38.335.73.451
rs69317986LRFN2C/T0.1380.22.3541.76.47.75
rs120336551DAB1C/T0.3750.27.3578.49.83.24
rs130239832FIGNA/C0.1420.24.3706.94.79.78
rs9990511PRELPC/T0.1690.12.3752.5.24.72
rs220692020BMP2A/G0.0850.1.3777.35.17.96
rs712472811LOC220070C/T0.3620.36.3818.52.93.27
rs1774811TREHC/T0.2330.23.3869.63.39.53
rs93692266LRFN2A/G0.1610.23.388.81.53.75
rs498068411FGF19C/T0.4080.41.4464.79.7.51
rs194111418CHST9A/G0.1580.13.4598.24.44.2
rs28536765TERTA/G0.2750.33.474.11.063.15
rs69146116PREPC/T0.10.08.4856.36.32.19
rs68695355PTGER4A/G0.1420.13.5073.65.64.37
rs812722021C21orf37A/G0.0670.06.5249.36.32.38
rs75627902CRIM1G/T0.3580.45.542.043.042.061
rs721955017POLR2AA/G0.1490.18.561.35.2.78
rs725711619MKNK2C/T0.3170.35.5779.68.38.7
rs44901272COL6A3G/T0.50.45.5914.079.028.81
rs1077101212SOX5A/G0.4750.47.59221.99.97
rs178937411RDXC/T0.2630.33.5969.96.83.8
rs117275644ANP32CG/T0.3080.29.6089.28.29.15
rs22246019C9orf123A/G0.2370.19.614.57.68.3
rs22087429C9orf123C/T0.2420.19.614.57.68.3
rs101979192FBLN7A/G0.4410.44.6147.74.51.91
rs10631929CDKN2A/BC/T0.40.49.6193.73.47.57
rs72767514HECTD1A/G0.4750.46.6268.91.7.95
rs49777569CDKN2A/BA/G0.3420.46.6423.49.3.35
rs604201820FKBP1AC/T0.4250.32.6454.61.91.33
rs48373349SH3GLB2A/G0.3170.3.6527.59.74.41
rs676117POLR2AC/T0.3920.4.6562.83.99.56
rs21802731TRIM67C/T0.1780.2.669.43.56.22
rs8331412PDE1AG/T0.1080.11.675.45.71.21
rs385389417ZBTB4A/G0.50.16.694.55.28.64
rs13848474RASL11BA/G0.0670.06.6975.71.76.41
rs10799506PARK2A/G0.2770.37.7238.49.29.41
rs75944322DNMT3AC/T0.3830.39.7306.76.55.55
rs116821752VRK2C/T0.4250.43.7381.89.68.71
rs8702831CAMTA1C/T0.4420.35.75.7.78.39
rs37486991UCK2A/G0.1330.12.755.088.12.075
rs168528681UCK2A/C0.1290.12.758.088.12.075
rs1008280412FLJ23560C/T0.0850.16.7625.32.22.53
rs104886317TNPO3C/T0.1670.11.7687.95.76.97
rs125317117TNPO3A/G0.1670.11.7687.95.76.97
rs78623159USP20A/G0.0880.13.7837.78.5.96
rs990164317POLR2AA/G0.150.16.7938.58.48.61
rs19980271TRIM67A/G0.320.46.7943.36.18.97
rs101700212BBS5C/T0.2170.31.7967.57.55.3
rs49887211PHLDB1C/T0.3250.33.8101.79.96.52
rs148487418SLC14A2A/G0.3920.44.8147.95.91.79
rs21577199CDKN2A/BA/G0.3830.48.8165.54.28.92
rs169041408CCDC26A/G0.1580.23.8389.37.35.2
rs66627471CAMTA1A/G0.480.42.8448.84.97.57
rs118871202DNMT3AC/T0.3560.37.8568.57.88.3
rs952668913DLEU7A/G0.0580.05.8623.7.85.50
rs42956278CCDC26G/T0.1420.2.8643.49.28.45
rs26789192VRK2A/G0.2580.25.865.64.68.46
rs732544313LIG4C/T0.170.22.9011.27.33.3
rs2651201GPATCH2C/T0.1020.15.9162.82.57.72
rs47384428JPH1C/T0.0750.03.9236.69.67.49
rs730068612TMEM132CC/T0.4570.41.9255.41.77.19
rs995977618LOC728662G/T0.3580.45.9295.98.93.91
rs64707458CCDC26A/G0.1420.22.9459.8.55.92
rs224398821RUNX1C/T0.3310.38.9521.75.56.8
rs14128299CDKN2A/BC/T0.3670.47.9671.68.44.92
rs609236120TFAP2CC/G0.1910.38.9793.93.8.71
rs27361005TERTG/T0.450.41.9916.85.58.8
rs92770414HECTD1A/C0.4250.44.9958.96.87.86
rs20725322SLC8A1C/T0.4580.43.1120.058.022.15

Abbreviations: SNP, single nucleotide polymorphism; GWAS, genome-wide association study; Chr, chromosome; MAF, minor allele frequency; NCBI, National Center for Biotechnology Information; MDACC, M. D. Anderson Cancer Center.

*MAF for CEU in the NCBI dbSNPs database.
Log-rank test P value for overall survival.
P value for difference in genotype distributions between long-term survivors and short-term survivors.

Table A3.

Association Between Genotype and Overall Survival in UCSF and Sweden Replication Groups

Gene and SNPUCSF (N = 352)
Sweden (N = 191)
No. of PatientsNo. of DeathsMST (months)HR95% CINo. of PatientsNo. of DeathsMST (months)HR95% CI
LIG4 rs7325927
    CC18216115.71Reference1059212.51Reference
    TC15312718.10.860.68 to 1.09655515.60.690.49 to 1.01
    TT1712150.790.44 to 1.446510.41.570.57 to 4.36
    TC + TT17013917.80.860.68 to 1.08716014.80.720.51 to 1.04
BTBD2 rs11670188
    AA21217817.81ReferenceNA
    AG11310114.51.311.03 to 1.68
    GG2721200.830.53 to 1.30
    AG + GG14012215.61.190.95 to 1.50
CCDC26 rs10464870
    TT22519416.31Reference1059413.41Reference
    TC1119317.11.050.82 to 1.35554414.70.950.64 to 1.40
    CC161316.91.190.68 to 2.09151313.60.950.51 to 1.80
    TC + CC12710617.11.060.84 to 1.35705714.30.950.66 to 1.36
CCDC26 rs891835
    TT21017817.81Reference1039312.91Reference
    TG12310714.81.310.99 to 1.67594814.70.950.66 to 1.39
    GG191518.11.100.65 to 1.87161314.60.780.41 to 1.47
    TG + GG14212214.91.290.98 to 1.63756114.60.910.64 to 1.29
RTEL1 rs2297440
    CC25121615.91Reference11410013.11Reference
    TC957918.61.050.81 to 1.37574815.21.110.77 to 1.61
    TT4319.40.730.23 to 2.296511.91.390.55 to 3.51
    TC + TT998218.61.030.8 to 1.34635314.51.140.80 to 1.62

Abbreviations: UCSF, University of California San Francisco; MST, median survival time; HR, hazard ratio; NA, not available.

*Adjusted for age and sex.

Table A4.

Comparing the Genotype Frequency Distribution Difference Among the Three Study Populations

Gene and SNPPatients
χ2 Test P
MDACC (N = 590)UCSF (N = 352)Sweden (N = 191)
LIG4 rs7325927
    CC309182105MDACC–UCSF, P = .002
    TC21715365MDACC–Sweden, P = .008
    TT64176UCSF–Sweden, P = .208
CCDC26 rs10464870
    TT350225105MDACC–UCSF, P = .356
    TC21011155MDACC–Sweden, P = .204
    CC311615UCSF–Sweden, P = .171
CCDC26 rs891835
    TT335210103MDACC–UCSF, P = .646
    TG22412359MDACC–Sweden, P = .155
    GG321916UCSF–Sweden, P = .287
RTEL1 rs2297440
    CC391251114MDACC–UCSF, P = .056
    TC1799557MDACC–Sweden, P = .885
    TT1946UCSF–Sweden, P = .074

Abbreviations: MDACC, M. D. Anderson Cancer Center; UCSF, University of California San Francisco.

Footnotes

Supported by Grants No. 5R01CA119215, 5R01CA070917, and K07CA093592 from the National Institutes of Health (to M. D. Anderson); the American Brain Tumor Association and the National Brain Tumor Society; The Wellcome Trust; Grant No. R01CA52689 from the National Institutes of Health; University of California, San Francisco (UCSF) Brain Tumor SPORE P50CA097257 (to University of California, San Francisco); the Swedish Research Council; Umeå University Hospital excellence grant; the Cancer Foundation of Northern Sweden; the Swedish Cancer Society; Grant LSHC-CT-2004-502943 Mol Cancer Med from the European Union; and by acta oncologica through the Royal Swedish Academy of Science (to the Swedish centre).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None Consultant or Advisory Role: None Stock Ownership: None Honoraria: None Research Funding: Terri Armstrong, Schering-Plough, Genentech Expert Testimony: None Other Remuneration: None

AUTHOR CONTRIBUTIONS

Conception and design: Yanhong Liu, Sanjay Shete, Richard Houlston, Melissa Bondy

Financial support: Sanjay Shete, Carol J. Etzel, Margaret Wrensch, Beatrice S. Melin, Melissa Bondy

Administrative support: Melissa Bondy

Provision of study materials or patients: Georgina Armstrong, Mark Gilbert, Ken Aldape, Terri Armstrong, Yuanyuan Xiao, John Wiencke, Margaret Wrensch, Beatrice S. Melin, Melissa Bondy

Collection and assembly of data: Georgina Armstrong, Spyros Tsavachidis, Mark Gilbert, Ken Aldape, Terri Armstrong, John Wiencke, Ulrika Andersson

Data analysis and interpretation: Yanhong Liu, Sanjay Shete, Carol J. Etzel, Michael Scheurer, Fu-Wen Liang, Richard Houlston, Fay Hosking, Lindsay Robertson, Yuanyuan Xiao, Margaret Wrensch, Ulrika Andersson, Beatrice S. Melin, Melissa Bondy

Manuscript writing: Yanhong Liu

Final approval of manuscript: Yanhong Liu, Sanjay Shete, Carol J. Etzel, Michael Scheurer, George Alexiou, Georgina Armstrong, Spyros Tsavachidis, Fu-Wen Liang, Mark Gilbert, Ken Aldape, Terri Armstrong, Richard Houlston, Fay Hosking, Lindsay Robertson, Yuanyuan Xiao, John Wiencke, Margaret Wrensch, Ulrika Andersson, Beatrice S. Melin, Melissa Bondy

REFERENCES

1. Holland EC. Glioblastoma multiforme: The terminator. Proc Natl Acad Sci U S A. 2000;97:6242–6244. [PMC free article] [PubMed]
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. [PubMed]
3. Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol. 1999;46:183–188. [PubMed]
4. Curran WJ, Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–710. [PubMed]
5. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–198. [PubMed]
6. Colman H, Aldape K. Molecular predictors in glioblastoma: Toward personalized therapy. Arch Neurol. 2008;65:877–883. [PubMed]
7. Martinez R, Schackert G, Yaya-Tur R, et al. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol. 2007;83:91–93. [PubMed]
8. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596–2606. [PubMed]
9. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. [PMC free article] [PubMed]
10. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. [PMC free article] [PubMed]
11. Bredel M, Scholtens DM, Harsh GR, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA. 2009;302:261–275. [PubMed]
12. Wang L, Wei Q, Wang LE, et al. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006;24:1627–1632. [PubMed]
13. Scheurer ME, Amirian E, Cao Y, et al. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res. 2008;14:6640–6646. [PMC free article] [PubMed]
14. Bhowmick DA, Zhuang Z, Wait SD, et al. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res. 2004;64:1220–1223. [PubMed]
15. Vauleon E, Auger N, Benouaich-Amiel A, et al. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet. 2007;172:33–37. [PubMed]
16. Rodero M, Marie Y, Coudert M, et al. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol. 2008;26:5957–5964. [PubMed]
17. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904. [PubMed]
18. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41:905–908. [PMC free article] [PubMed]
19. Liu Y, Scheurer ME, El-Zein R, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204–214. [PMC free article] [PubMed]
20. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–442. [PubMed]
21. Wakefield J. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am J Hum Genet. 2007;81:208–227. [PMC free article] [PubMed]
22. Therneau T, Atkinson B. Rochester, MN: Department of Health Science Research, Mayo Clinic; 1997. Technical Report Series No. 61, An Introduction to Recursive Partitioning Using the RPART Routines.
23. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293:557–564. [PubMed]
24. Central Brain Tumor Registry of the United States. Chicago, IL: Central Brain Tumor Registry of the United States; 2008. SEER: Statistical report: Primary brain tumors in the United States, 2000-2004.
25. Liu Y, Zhou K, Zhang H, et al. Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma. Hum Mutat. 2008;29:381–389. [PubMed]
26. Roddam PL, Rollinson S, O'Driscoll M, et al. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet. 2002;39:900–905. [PMC free article] [PubMed]
27. Goode EL, Dunning AM, Kuschel B, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 2002;62:3052–3057. [PubMed]
28. Xu L, Yang L, Hashimoto K, et al. Characterization of BTBD1 and BTBD2, two similar BTB-domain-containing Kelch-like proteins that interact with Topoisomerase I. BMC Genomics. 2002;3:1. [PMC free article] [PubMed]
29. Champoux JJ. DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem. 2001;70:369–413. [PubMed]
30. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol. 2002;3:430–440. [PubMed]
31. Bredel M, Piribauer M, Marosi C, et al. High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur J Cancer. 2002;38:1343–1347. [PubMed]
32. Yin W, Rossin A, Clifford JL, et al. Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM. Oncogene. 2006;25:3735–3744. [PubMed]
33. Jiang M, Zhu K, Grenet J, et al. Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim Biophys Acta. 2008;1783:1055–1067. [PMC free article] [PubMed]
34. Das A, Banik NL, Ray SK. Differentiation decreased telomerase activity in rat glioblastoma C6 cells and increased sensitivity to IFN-gamma and taxol for apoptosis. Neurochem Res. 2007;32:2167–2183. [PubMed]
35. Li AY, Boo LM, Wang SY, et al. Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res. 2009;69:5699–5706. [PMC free article] [PubMed]
36. Cleynen I, Van de Ven WJ. The HMGA proteins: A myriad of functions (Review) Int J Oncol. 2008;32:289–305. [PubMed]
37. Barber LJ, Youds JL, Ward JD, et al. RTEL1 maintains genomic stability by suppressing homologous recombination. Cell. 2008;135:261–271. [PMC free article] [PubMed]
38. Little MP, De Vathaire F, Shamsaldin A, et al. Risks of brain tumour following treatment for cancer in childhood: Modification by genetic factors, radiotherapy and chemotherapy. Inter J Cancer. 1998;78:269–275. [PubMed]
39. Bondy ML, Wang LE, El-Zein R, et al. Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst. 2001;93:1553–1557. [PubMed]
40. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: A report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98:1528–1537. [PubMed]
41. Mueller JC, Lohmussaar E, Magi R, et al. Linkage disequilibrium patterns and tagSNP transferability among European populations. Am J Hum Genet. 2005;76:387–398. [PMC free article] [PubMed]
42. Lundmark PE, Liljedahl U, Boomsma DI, et al. Evaluation of HapMap data in six populations of European descent. Eur J Hum Genet. 2008;16:1142–1150. [PubMed]
43. Morgan TM, Krumholz HM, Lifton RP, et al. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA. 2007;297:1551–1561. [PubMed]
44. Gorroochurn P, Hodge SE, Heiman GA, et al. Non-replication of association studies: “pseudo-failures” to replicate? Genet Med. 2007;9:325–331. [PubMed]
45. Clarke GM, Carter KW, Palmer LJ, et al. Fine mapping versus replication in whole-genome association studies. Am J Hum Genet. 2007;81:995–1005. [PMC free article] [PubMed]
46. Liu YJ, Papasian CJ, Liu JF, et al. Is replication the gold standard for validating genome-wide association findings? PLoS One. 2008;3:e4037. [PMC free article] [PubMed]

Articles from Journal of Clinical Oncology are provided here courtesy of American Society of Clinical Oncology

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...